Dennis Hahn

Stuttgart, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117).

Journal: British journal of cancer

Published: December 17, 2025

Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial.

Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial.

Journal: Cancer treatment and research communications

Published: July 29, 2025

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 17, 2025

Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115).

Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115).

Journal: Oncology research and treatment

Published: April 05, 2025

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Journal: Annals of hematology

Published: March 26, 2025

Highlights from ESMO 2024 as a Young Head and Neck Oncologist.

Highlights from ESMO 2024 as a Young Head and Neck Oncologist.

Journal: Oncology research and treatment

Published: January 07, 2025

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.

Journal: NPJ precision oncology

Published: December 09, 2024

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

Journal: Med (New York, N.Y.)

Published: October 30, 2024

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Journal: Frontiers in oncology

Published: August 25, 2023

Osteosarcomas in older adults: A report from the Cooperative Osteosarcoma Study Group.

Osteosarcomas in older adults: A report from the Cooperative Osteosarcoma Study Group.

Journal: Journal of geriatric oncology

Published: September 27, 2022

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.

Journal: Cancers

Published: September 12, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026